Infinity Pharmaceuticals Inc. (NASDAQ:INFI) saw unusually-high trading volume on Thursday . Approximately 1,494,672 shares were traded during trading, an increase of 545% from the previous session’s volume of 231,661 shares.The stock last traded at $1.91 and had previously closed at $1.54.
INFI has been the subject of a number of research reports. ValuEngine upgraded Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 4th. B. Riley initiated coverage on Infinity Pharmaceuticals in a report on Friday, January 4th. They set a “buy” rating and a $3.00 target price for the company. Zacks Investment Research cut Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 7th. Finally, UBS Group reiterated a “reduce” rating on shares of Infinity Pharmaceuticals in a report on Monday, January 7th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $2.83.
The firm has a market capitalization of $81.89 million, a PE ratio of -2.30 and a beta of 2.17.
Infinity Pharmaceuticals Company Profile (NASDAQ:INFI)
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
See Also: Analyst Ratings Trading
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.